51results about How to "Improve apparent solubility" patented technology

The invention uses liquefying enzyme ejecting method to produce low DE value malt dextrin, the invention refers to a kind of enzyme project manufacturing method of low DE value malt dextrin and the application. The invention uses core starch or indica rice powder as materials, uses the special device steam ejecting liquefying device and laminar current device, the product whose DE value is 2-6 is obtained through ejecting, thermal retardation and liquefying, enzyme eliminating process. The product with 5-6 DE value can be used in solid chrysanthemum flower essence beverage to replace 66% sugar powder and decrease 60% chrysanthemum extracting solution; the product with 2-3 DE value can be used in the production of gammon and icecream, the 50% aft in gammon and icecream can be replaced by malt dextrin, 30 g fat in gammon can be replaced with 6-7.5 g malt dextrin, 4 g fat in icecream can be replaced with 1 g malt dextrin. The invention fills the blank of low DE value malt dextrin in our country.

The invention discloses a capsaicin beta-cyclodextrin inclusion compound, as well as liposome and gel thereof. The capsaicin beta-cyclodextrin inclusion compound is prepared by the following method: (1) beta-cyclodextrin is dissolved in an aqueous phase and prepared into a solution, and the solution is added with capsaicin or a capsaicin solution so as to obtain a mixed solution of capsaicin and beta-cyclodextrin; and (2) the solution-type capsaicin beta-cyclodextrin inclusion compound is obtained from the mixed solution prepared in a step (1) through at least one treatment mode of standing, heating, stirring, ultrasound or grinding. The apparent solubility of the capsaicin of the inclusion compound increases by 2 to 20 times. In vitro transdermal study shows that the capsaicin inclusion compound can obviously raise the transdermal rate of medicine by 5 to 20 times as compared with cream and hydrogel, and obviously reduce the irritation of capsaicin at skin. Besides transdermal drug administration, the prepared inclusion compound and the inclusion compound liposome can also be orally taken, injected or administrated in bladders. In addition, the invention is simple in production process, and the quality is stable and easy to control.

The invention discloses a method for enhancing biodegradation of hydrophobic methylbenzene, and belongs to the field of volatile organic compound treatment technologies. The method comprises the following steps: adopting bacteria obtained by performing methylbenzene gradient domestication on activated sludge from a wastewater treatment plant; preparing a bacterium suspension for later use after enlarged cultivation; adopting expanded clay aggregate as a filler for a bio-trickling filter, and laying the filler layer by layer; spraying the bacterium suspension to the expanded clay aggregate uniformly from the upper part of the bio-trickling filter; feeding high-concentration methylbenzene gas from the bottom of the bio-trickling filter for further domestication; starting the bio-trickling filter in a gas-phase domestication biofilm-culturing manner, forming biofilms, and enabling the bio-trickling filter to enter the next stable operation stage; adding rhamnolipid, a biosurfactant, to a circulating nutrient solution; spraying the circulating nutrient solution to the filler from the upper part of the bio-trickling filter to allow the rhamnolipid to distribute uniformly on the filler along with the circulating nutrient solution through a liquid distribution board; feeding waste methylbenzene gas to be treated from the bottom of the bio-trickling filter. The method has the advantages that the operation is simple, no secondary pollution is generated, and the biodegradation efficiency of hydrophobic methylbenzene, a VOC (Volatile Organic Compound), can be increased.

The invention discloses a method for preparing low-density maltodextrin, which comprises the step of taking corn or rice or tubers as a raw material, and steps of size mixing, spraying and liquefying, micropore refining and spray drying to obtain the product. The method improves and optimizes the prior producing technology of the maltodextrin, namely preparing starch to have low density suitable for liquefying enzyme and have a pH value of between 3 and 5, spraying and liquefying the starch twice by high temperature, and refining the starch by a micropore. The density of the product prepared by the spray drying reaches less than 0.10 g / cm<3>; and the product is in shape of hollow ball, and has the advantages of large apparent solubility, low sweetness, low hydroscopic property, no easy caking, and the like.

The invention belongs to the technical field of high polymer chemistry, biomedical materials and pharmacy, and particularly discloses ciclosporin A eye drops and a preparation method thereof. Every 1,000 mL of the eye drops are prepared from the following substances: ciclosporin A 30-630 mg, a polymer-grafted copolymer 1-10 g, and the balance of injection water, wherein the polymer-grafted copolymer is chitosan-g-cyclodextrin. The preparation method comprises the following steps: firstly, weighing the chitosan-g-cyclodextrin as the polymer-grafted copolymer, adding and dissolving equivalent injection water in the chitosan-g-cyclodextrin, and stirring and dissolving until a solution is transparent; secondly, adding an ethanol solution of the ciclosporin A in the solution, stirring at the temperature of 0-4 DEG C until a system becomes completely clear; thirdly, removing ethanol under reduced pressure at the temperature of 0-4 DEG C and washing; and finally, adding the injection water and determining the volume, and sterilizing to obtain the final product. The eye drops have the advantages that irritation of the medicine is reduced, the residence time of the medicine on an ocular surface is prolonged, the corneal permeability of the medicine is improved, and the treatment effect of the medicine is also improved.

The invention relates to a wastewater treatment integrated device and method for a composite catalytic oxidation coupled biological filter. The wastewater treatment integrated device consists of a gas-liquid mixer, a composite catalytic oxidation coupled biological filter apparatus, an energy field generator and an ozone generator. The wastewater treatment integrated device can effectively improvethe ozone utilization efficiency, oxygen utilization rate, pollutant degradation efficiency, system impact resistance and effluent water quality, and can reduce the investment and treatment cost.

The invention discloses an olaparib and malonic acid eutectic crystal and a preparation method thereof. In the eutectic crystal, the molar ratio of olaparib to malonic acid is 1: 1; the eutectic X-raypowder diffraction pattern has characteristic peaks when the 2theta value is at the positions of 9.8 + / -0.2 degrees, 12.4 + / -0.2 degrees, 12.6 + / -0.2 degrees, 13.4 + / -0.2 degrees, 16.2 + / -0.2 degrees, 17.5 + / -0.2 degrees, 18.7 + / -0.2 degrees and 21.0 + / -0.2 degrees. The eutectic preparation method is simple in process, easy to control the crystallization process, good in reproducibility and suitable for industrial production. Compared with olaparib free alkali, the eutectic crystal has higher apparent solubility, and is beneficial to improving the oral absorption efficiency of olaparib.

The invention discloses an olaparib and maleic acid cocrystal and a preparation method thereof. The molar ratio of olaparib to maleic acid in the cocrystal is 1:1, and an X-ray powder diffraction pattern of the cocrystal has characteristic peaks when the 2theta values are 5.1+ / -0.2 degrees, 9.8+ / -0.2 degrees, 13.7+ / -0.2 degrees, 16.0+ / -0.2 degrees, 17.7+ / -0.2 degrees and 20.0+ / -0.2 degrees. The cocrystal preparation method provided by the invention is simple in process, easy to control the crystallization process, good in reproducibility and suitable for industrial production. Compared with olaparib free alkali, the cocrystal has higher apparent solubility, and is beneficial to improving the oral absorption efficiency of olaparib.

The invention provides an integral composite catalytic oxidation-membrane separation wastewater treatment method which comprises the following steps: S1, introducing wastewater with a suspension catalyst, a mixed gas of ozone and oxygen and hydrogen peroxide into a gas-liquid mixer; S2, introducing the wastewater into a composite catalytic oxidation reactor, and inputting into an energy field through an energy field generation device; S3, filtering the wastewater by using a ceramic membrane filter, performing up-to-standard emission on effluent, emptying the treated gas, and feeding back membrane concentrated water which does not pass through the ceramic membrane filter and contains the suspension catalyst to the step S1. Devices used in the method provided by the invention comprise one gas-liquid mixer which can generate micro-nano bubbles, so that the apparent solubility of ozone and oxygen in the wastewater can be effectively improved, and the catalytic oxidation efficiency can be improved. Due to adoption of the energy field generation device, microwaves, ultrasonic waves, the catalyst and an oxidant have synergic effects in a composite catalytic oxidation reactor, so that the degradation velocity of pollutants by the oxidant can be increased.

The invention discloses a compounded ophthalmic preparation which comprises a solid component A and a component B, wherein the component B is used as a buffer isotonic solution; the component A comprises a chondroitin sulfate cross-linking modified carboxylated beta-cyclodextrin carrier as well as components, namely sodium hyaluronate, trehalose, glycine betaine and alanyl glutamine matrix which are carried by the carrier; and the component B as the buffer isotonic solution comprises povidone, taurine, glycerinum and / or a sodium chloride isotonic agent, an antibacterial agent, a pH value adjusting agent and injection water. The preparation disclosed by the invention is used for alleviating asthenopia and relieving xerophthalmia symptoms, has very high stability and can be preserved for a long time without a preservative.

The invention belongs to the technical fields of high polymer chemistry, biomedical materials and pharmacy and particularly discloses eye drops with a polymer-grafted copolymer as a carrier and a preparation method of the eye drops. Each 1000mL of the eye drops are prepared from the following materials: 2g to 30g of eye drops medicament, 10g to 200g of polymer-grafted copolymer, 0.5g to 20g of hydroxysuccinic acid, and the balance of water for injection, wherein the polymer-grafted copolymer is chitosan-g-cyclodextrin. The preparation method comprises the following steps: firstly, weighing the chitosan-g-cyclodextrin serving as the polymer-grafted copolymer, adding the water with dissolved equivalent amount for injection into the chitosan-g-cyclodextrin, and stirring and dissolving until a transparent solution is obtained; secondly, adding the eye drops medicament and the hydroxysuccinic acid into the solution, and stirring to be completely dissolved; finally, adding the water for injection, metering the volume, and sterilizing to obtain the eye drops. After the eye drops disclosed by the invention is applied to an ocular surface, the eye drops have the following predominant advantages that the irritation of the medicament is reduced, the detention time of the medicament on the ocular surface is prolonged, the corneal permeability of the medicament is improved, and the treatment effect of the medicament is improved.

The invention discloses dexlansoprazole-isonicotine eutectic and application of the eutectic. The eutectic is a crystalline complex combined by dexlansoprazole and isonicotine at a mole ratio of 1:1 in a non-covalent form; an X-ray powder diffraction spectrum of the eutectic comprises diffraction peaks expressed by the following 2 theta angles: 5.3-5.5 degrees, 10.7-10.9 degrees, 12.8-13.0 degrees, 14.9-15.1 degrees, 16.1-16.3 degrees, 18.4-18.6 degrees, 19.1-19.3 degrees, 19.9-20.1 degrees, 22.0-22.2 degrees, 22.6-22.8 degrees, 24.3-24.5 degrees, 25.8-26.0 degrees, 26.2-26.4 degrees, 27.0-27.2 degrees, 27.4-27.6 degrees, 31.4-31.6 degrees and 32.5-32.7 degrees. Compared with the prior art, the dexlansoprazole-isonicotine eutectic is excellent in crystal form stability and high in bioavailability, and has greater maximum apparent solubility in ultrapure water; a preparation method of the dexlansoprazole-isonicotine eutectic is simple, mild in condition and high in repeatability; a product can be conveniently, quickly and stably obtained; the crystal form purity of the product is high; obvious raw material impurities and residual solvents do not exist.

The invention discloses an olaparib-urea eutectic crystal and a preparation method thereof. In the eutectic crystal, a molar ratio of olaparib to urea is 1: 2; in an X-ray powder diffraction pattern of the eutectic crystal, characteristic peaks occur when the value of 2theta is 6.4 + / - 0.2 degrees, 14.3 + / - 0.2 degrees, 15.0 + / - 0.2 degrees, 18.6 + / - 0.2 degrees, 19.2 + / - 0.2 degrees, 24.3 + / -0.2degrees and 24.8 + / -0.2 degrees. The preparation method of the eutectic crystal provided by the invention is simple in process, a crystallization process is easy to control, good in reproducibility and suitable for industrial production. Compared with olaparib free alkali, the eutectic crystal has higher apparent solubility and is beneficial to improving the oral absorption efficiency of olaparib.

The invention discloses a lenvatinib and p-hydroxybenzoic acid eutectic crystal and a preparation method thereof. The eutectic crystal comprises lenvatinib and p-hydroxybenzoic acid in a molar ratio of 1: 1, an X-ray powder diffraction pattern of the eutectic crystal measured by Cu K alpha rays has characteristic peaks when diffraction angles 2theta are 6.3+ / -0.2 degrees, 10.6+ / -0.2 degrees, 12.4+ / -0.2 degrees, 14.6+ / -0.2 degrees, 17.5+ / -0.2 degrees and 18.4+ / -0.2 degrees. According to the preparation method, the lenvatinib is converted into a brand-new lenvatinib and p-hydroxybenzoic acid eutectic crystal for the first time, and the lenvatinib and p-hydroxybenzoic acid eutectic crystal has a relatively high dissolution rate and relatively high apparent solubility. The preparation method of the lenvatinib and p-hydroxybenzoic acid eutectic crystal is simple in process, easy to control the crystallization process, good in reproducibility, suitable for industrial production and wide in application prospect.

The invention discloses a new crystal form of axitinib fumarate and a preparation method thereof. In the new crystal form, the molar ratio of axitinib to fumaric acid is 1: 1.5, and the X-ray powder diffraction pattern of the crystal form has characteristic peaks when the 2 theta value is 7.1 + / -0.2 degrees, 12.5 + / -0.2 degrees, 15.1 + / -0.2 degrees, 17.4 + / -0.2 degrees and 23.4 + / -0.2 degrees. Thecrystal form preparation method provided by the invention is simple in process, easy in crystallization process control, good in reproducibility and suitable for industrial production. The new crystal form of the axitinib fumarate is remarkably improved in the aspects of light stability and dissolution property, and is beneficial to improving the safety and oral bioavailability of axitinib.

The invention discloses a lenvatinib and benzoic acid eutectic crystal and a preparation method thereof, wherein in the eutectic crystal, the molar ratio of lenvatinib to benzoic acid is 1:1, and theeutectic X-ray powder diffraction pattern has characteristic peaks when the 2theta values are 6.4+ / -0.2 degrees, 7.4+ / -0.2 degrees, 12.5+ / -0.2 degrees, 14.7+ / -0.2 degrees, 16.7+ / -0.2 degrees, 17.7+ / -0.2 degrees and 23.8+ / -0.2 degrees. According to the invention, the eutectic preparation method is simple in process, easy to control the crystallization process, good in reproducibility and suitable for industrial production; and compared with lenvatinib mesylate, the eutectic crystal of the invention has low hygroscopicity, high dissolution rate and high apparent solubility, and provides a material basis for improving the stability and oral absorption efficiency of lenvatinib and reducing the process threshold and cost of a preparation.

The invention relates to a method for repairing DDTs contaminated soil by using a composite lotion, and application thereof, and belongs to the technical field of environmental chemistry. According to the invention, the absorption of plants to DDTs and the degradation of the plants in rhizosphere soil are improved by utilizing the solubilizing effect of the synergistic composite lotion compounded by the surfactant Tween80 and the green organic solvent ethyl lactate on strong-hydrophobicity DDTs in a manner of promoting the plants to repair the DDTs polluted soil through the synergistic composite lotion; and the synergistic composite lotion is regularly applied to soil in a spraying mode, meanwhile, the moisture content of the soil is strictly controlled, the percolation phenomenon is avoided, plant growth is facilitated, mixing, conveying and uniform distribution of effective components in the synergistic composite lotion are facilitated, the risk of secondary pollution is reduced, and the remediation efficiency is improved. The method has the advantages of being economical, efficient, easy to operate, wide in applicable soil type, capable of achieving in-situ remediation, small in influence on the original environment, capable of reducing the risk of secondary pollution and beneficial to soil recycling.

The invention discloses a spray drier which comprises a gas heater, a dry tower, a heat distributor and a sprayer, wherein the gas heater is communicated with the heat distributor arranged on the top of the dry tower through a hot air pipe; and the sprayer is installed on the top of the inside of the dry tower. The spray drier also comprises a tubular heater, wherein the tubular heater is communicated with a feeding pump through a feeding pipe; and the feeding pump is communicated with the material inlet of the dry tower through the feeding pipe. By using the spray drier, the uneven granularity problem caused by the fact that materials suddenly contact high temperature is avoided; dry quality of a product is good, and the product with an ultra-low density can be produced; and the product has the advantages of good dispersibility, flowability and solubility.

The invention discloses a penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal and a preparation method thereof. In the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal, the molar ratio of penciclovir to 3,5-dihydroxybenzoic acid is 1:1. The preparation method of the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal is simple in process, the crystallization process is easyto control, the reproducibility is good, and the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal is suitable for industrial production. Compared with penciclovir, the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal has the advantages that the dissolution rate is higher, the apparent solubility is higher, the bioavailability of the penciclovir is favorably improved, and a material basis is provided for successfully developing oral preparations and liquid preparations of penciclovir.

The invention belongs to the technical field of high polymer chemistry, biomedical materials and pharmacy, and particularly discloses ciclosporin A eye drops and a preparation method thereof. Every 1,000 mL of the eye drops are prepared from the following substances: ciclosporin A 30-630 mg, a polymer-grafted copolymer 1-10 g, and the balance of injection water, wherein the polymer-grafted copolymer is chitosan-g-cyclodextrin. The preparation method comprises the following steps: firstly, weighing the chitosan-g-cyclodextrin as the polymer-grafted copolymer, adding and dissolving equivalent injection water in the chitosan-g-cyclodextrin, and stirring and dissolving until a solution is transparent; secondly, adding an ethanol solution of the ciclosporin A in the solution, stirring at the temperature of 0-4 DEG C until a system becomes completely clear; thirdly, removing ethanol under reduced pressure at the temperature of 0-4 DEG C and washing; and finally, adding the injection water and determining the volume, and sterilizing to obtain the final product. The eye drops have the advantages that irritation of the medicine is reduced, the residence time of the medicine on an ocular surface is prolonged, the corneal permeability of the medicine is improved, and the treatment effect of the medicine is also improved.

The invention provides a soil conditioner. The soil conditioner is prepared from the following raw materials in parts by weight: 20 to 30 parts of diatomite, 5 to 8 parts of polyacrylamide, 4 to 6 parts of polyvinyl alcohol, 50 to 70 parts of humic acid matrix, 3 to 5 parts of compound microbial agent, 5 to 10 parts of hydroxypropyl methyl cellulose and 4 to 8 parts of lauryl sodium sulfate. The diatomite-based porous ceramic particles are prepared by taking diatomite as a matrix, so that the ecological toxicity of organic pollutants can be reduced, the aim of immobilizing the pollutants is fulfilled, the concentration of the organic pollutants in a water-phase solution can be reduced, and the degradation of the organic pollutants by microorganisms is inhibited; in the invention, peat, lignite and weathered coal are used as matrixes, wherein the humic acid matrix is decomposed by bacteria or mould in the composite microbial agent to slowly release humic acid, so that heavy metal ions in soil can be fixed, degradation of organic matters such as pesticides and polycyclic aromatic hydrocarbons can be adsorbed and promoted, and therefore, enrichment and toxic effects of heavy metals inplants can be reduced, and the soil pollution condition can be alleviated.

The invention discloses a method for preparing low-density maltodextrin, which comprises the step of taking corn or rice or tubers as a raw material, and steps of size mixing, spraying and liquefying, micropore refining and spray drying to obtain the product. The method improves and optimizes the prior producing technology of the maltodextrin, namely preparing starch to have low density suitable for liquefying enzyme and have a pH value of between 3 and 5, spraying and liquefying the starch twice by high temperature, and refining the starch by a micropore. The density of the product prepared by the spray drying reaches less than 0.10 g / cm<3>; and the product is in shape of hollow ball, and has the advantages of large apparent solubility, low sweetness, low hydroscopic property, no easy caking, and the like.

The invention relates to fields of chemical pharmacy, pharmaceutical preparations, pharmacokinetics and pharmacodynamics and discloses a solid dispersion prepared from cyclovirobuxine D extracted fromBuxus micr ophylla Sieb.et Zucc.var.sinica Rehd.et Wils. and congeners and application of the solid dispersion to prevention and treatment of senile dementia. According to enzymological and animal experiments, the cyclovirobuxine D solid dispersion has a great senile dementia prevention and treatment function. According to further researches, activity of the cyclovirobuxine D solid dispersion isremarkably improved as compared with that of cyclovirobuxine D. The cyclovirobuxine D solid dispersion has the advantage that the a preparation method is simple, convenient and easy in operation, thecyclovirobuxine D solubility and intestinal mucosa permeation rate are greatly increased, and accordingly bioavailability is improved.

The invention discloses a compounded ophthalmic preparation which comprises a solid component A and a component B, wherein the component B is used as a buffer isotonic solution; the component A comprises a chondroitin sulfate cross-linking modified carboxylated beta-cyclodextrin carrier as well as components, namely sodium hyaluronate, trehalose, glycine betaine and alanyl glutamine matrix which are carried by the carrier; and the component B as the buffer isotonic solution comprises povidone, taurine, glycerinum and / or a sodium chloride isotonic agent, an antibacterial agent, a pH value adjusting agent and injection water. The preparation disclosed by the invention is used for alleviating asthenopia and relieving xerophthalmia symptoms, has very high stability and can be preserved for a long time without a preservative.

The invention discloses a co-crystal of lenvatinib and p-hydroxybenzoic acid and a preparation method thereof. This co-crystal contains lenvatinib and p-hydroxybenzoic acid in a molar ratio of 1:1; the X-ray powder diffraction pattern of the co-crystal measured with Cu Kα rays is 6.3±0.2°, 10.6±0.2 °, 12.4±0.2°, 14.6±0.2°, 17.5±0.2°, 18.4±0.2° have characteristic peaks. The present invention converts lenvatinib into a brand-new co-crystal of lenvatinib and p-hydroxybenzoic acid for the first time, and the co-crystal of lenvatinib and p-hydroxybenzoic acid has a faster dissolution rate and a larger apparent Solubility. The preparation method of the co-crystal of lenvatinib and p-hydroxybenzoic acid has simple process, easy control of the crystallization process, good reproducibility, is suitable for industrial production, and has broad application prospects.

The invention discloses a penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal and a preparation method thereof. In the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal, the molar ratio of penciclovir to 3,5-dihydroxybenzoic acid is 1:1. The preparation method of the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal is simple in process, the crystallization process is easyto control, the reproducibility is good, and the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal is suitable for industrial production. Compared with penciclovir, the penciclovir and 3,5-dihydroxybenzoic acid eutectic crystal has the advantages that the dissolution rate is higher, the apparent solubility is higher, the bioavailability of the penciclovir is favorably improved, and a material basis is provided for successfully developing oral preparations and liquid preparations of penciclovir.

The invention provides a method for chemical elution-plant combined repairing polychlorinated biphenyl contaminated soil, which belongs to the field of contaminated soil restoration, and comprises the following steps: taking the contaminated soil to be repaired, grinding and pulverizing, passing through a 60-mesh sieve, and adjusting the sieve The water content of the final soil should be adjusted to keep the soil water content at 40% to 60% of its field water capacity, and it will be used for later use; the alfalfa seeds that have been treated with germination will be evenly spread in the spare soil for cultivation, and the alfalfa plants will grow for two weeks. Thinning it afterward, the alfalfa plant cultivation period is 90 days; Begin to spray eluent in soil from thinning, spray once every 5 days to 8 days, thereby repair polychlorinated biphenyls in soil, and prior art Compared with the present invention, the operation is simple and the treatment effect is good, and in-situ restoration can be realized. The restoration process has little impact on the original environment, and a wide range of soil types are used. When used in actual environmental restoration, the risk of secondary pollution is greatly reduced, which is beneficial to subsequent soil restoration. Recycling.

The invention belongs to the technical fields of high polymer chemistry, biomedical materials and pharmacy and particularly discloses eye drops with a polymer-grafted copolymer as a carrier and a preparation method of the eye drops. Each 1000mL of the eye drops are prepared from the following materials: 2g to 30g of eye drops medicament, 10g to 200g of polymer-grafted copolymer, 0.5g to 20g of hydroxysuccinic acid, and the balance of water for injection, wherein the polymer-grafted copolymer is chitosan-g-cyclodextrin. The preparation method comprises the following steps: firstly, weighing the chitosan-g-cyclodextrin serving as the polymer-grafted copolymer, adding the water with dissolved equivalent amount for injection into the chitosan-g-cyclodextrin, and stirring and dissolving until a transparent solution is obtained; secondly, adding the eye drops medicament and the hydroxysuccinic acid into the solution, and stirring to be completely dissolved; finally, adding the water for injection, metering the volume, and sterilizing to obtain the eye drops. After the eye drops disclosed by the invention is applied to an ocular surface, the eye drops have the following predominant advantages that the irritation of the medicament is reduced, the detention time of the medicament on the ocular surface is prolonged, the corneal permeability of the medicament is improved, and the treatment effect of the medicament is improved.